Recurrent candida prosthetic endocarditis over fifteen years managed with medical therapy and four valvular surgeries: a case report and review of literature

Journal of Cardiothoracic Surgery

William H. Carter²  Sean Winfrey⁴  James D. Bergin¹  Curtis G. Tribble³  Bishnu P. Dhakal⁵ 

[1] Cardiology Division, University of Virginia, Charlottesville, VA, USA;Cardiology Division, West Virginia University, Charleston Division, Charleston, WV, USA;Cardiothoracic Surgery, University of Virginia, Charlottesville, VA, USA;West Virginia School of Osteopathic Medicine, Charleston, WV, USA;Department of Medicine, West Virginia University, Charleston Division, Charleston, WV, USA

关键词: Endocarditis;    Prosthetic;    Candida;   

Others  :  1224590
DOI  :  10.1186/s13019-015-0309-7

 received in 2015-03-20, accepted in 2015-07-20,  发布年份 2015

【 摘 要 】

Background

Candida prosthetic endocarditis (CPE) is an uncommon disease involving less than 1 % of infective endocarditis patients and associated with high recurrence rate. Immunosuppresion, intravenous drug abuse, cardiac surgery and indwelling foreign bodies are the major risk factors for CPE. There are very few reported cases of CPE where more than one surgery was performed and there has generally been limited follow up on these cases.

Case presentation

We report a case of a 35 year old woman who had mitral valve annuloplasty complicated by recurrent episodes of CPE leading to multiple mitral valve replacements (MVR). She underwent MVR surgeries a total of four times over an eighteen year period and had good functionality during most of this time while being on antifungal suppressive treatment. This is a unique case in terms of numbers of surgeries performed, the length of the follow up and the involvement of three different Candida species.

Conclusion

Current guidelines for the treatment of candida endocarditis recommend surgical treatment followed by long term antifungal therapy although the cure rate by all treatments is low. However we feel that based on this one case it is reasonable to consider multiple redo valve replacement surgeries in conjunction with antifungal treatment for selected patients stable enough to tolerate the surgery.

【 授权许可】

   
2015 Dhakal et al.

【 参考文献 】

• [1]Muehrcke DD, Lytle BW, Cosgrove DM. Surgical and long-term antifungal therapy for fungal prosthetic valve endocarditis. Ann Thorac Surg. 1995; 60:538-43.
• [2]Boland JM, Chung HH, Robberts FJ, Wilson WR, Steckelberg JM, Baddour LM, Miller DV. Fungal prosthetic valve endocarditis: Mayo Clinic experience with a clinicopathological analysis. Mycoses. 2011; 54:354-60.
• [3]Muehrcke DD. Fungal prosthetic valve endocarditis. Semin Thorac Cardiovasc Surg. 1995; 7:20-4.
• [4]Falcone M, Barzaghi N, Carosi G, Grossi P, Minoli L, Ravasio V, Rizzi M, Suter F, Utili R, Viscoli C, Venditti M. Candida infective endocarditis: report of 15 cases from a prospective multicenter study. Medicine. 2009; 88:160-8.
• [5]Pierrotti LC, Baddour LM. Fungal endocarditis, 1995–2000. Chest. 2002; 122:302-10.
• [6]Sousa C, Botelho C, Rodrigues D, Azeredo J, Oliveira R. Infective endocarditis in intravenous drug abusers: an update. Eur J Clin Microbiol Infect Dis. 2012; 31:2905-10.
• [7]Grunberg W, Al-Bataineh M, Weiss S. Candida albicans endocarditis with giant vegetation from an implantable cardioverter-defibrillator lead. Surg Infect (Larchmt). 2013; 14:157-9.
• [8]Wallner M, Steyer G, Krause R, Gstettner C, von Lewinski D. Fungal endocarditis of a bioprosthetic aortic valve. Pharmacological treatment of a Candida parapsilosis endocarditis. Herz. 2013; 38:431-4.
• [9]Lefort A, Chartier L, Sendid B, Wolff M, Mainardi JL, Podglajen I, Desnos-Ollivier M, Fontanet A, Bretagne S, Lortholary O. Diagnosis, management and outcome of Candida endocarditis. Clin Microbiol Infect. 2012; 18:E99-E109.
• [10]Ellis ME, Al-Abdely H, Sandridge A, Greer W, Ventura W. Fungal endocarditis: evidence in the world literature, 1965–1995. Clin Infect Dis. 2001; 32:50-62.
• [11]Baddley JW, Benjamin DK, Patel M, Miro J, Athan E, Barsic B, Bouza E, Clara L, Elliott T, Kanafani Z, Klein J, Lerakis S, Levine D, Spelman D, Rubinstein E, Tornos P, Morris AJ, Pappas P, Fowler VG, Chu VH, Cabell C. Candida infective endocarditis. Eur J Clin Microbiol Infect Dis. 2008; 27:519-29.
• [12]Ramage G, Vandewalle K, Wickes BL, Lopez-Ribot JL. Characteristics of biofilm formation by Candida albicans. Rev Iberoam Micol. 2001; 18:163-70.
• [13]Cornely OA, Bassetti M, Calandra T, Garbino J, Kullberg BJ, Lortholary O, Meersseman W, Akova M, Arendrup MC, Arikan-Akdagli S, Bille J, Castagnola E, Cuenca-Estrella M, Donnelly JP, Groll AH, Herbrecht R, Hope WW, Jensen HE, Lass-Florl C, Petrikkos G, Richardson MD, Roilides E, Verweij PE, Viscoli C, Ullmann AJ. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect. 2012; 18 Suppl 7:19-37.
• [14]Pappas PG, Kauffman CA, Andes D, Benjamin DK, Calandra TF, Edwards JE, Filler SG, Fisher JF, Kullberg BJ, Ostrosky-Zeichner L, Reboli AC, Rex JH, Walsh TJ, Sobel JD. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009; 48:503-35.
• [15]Prabhu RM, Orenstein R. Failure of caspofungin to treat brain abscesses secondary to Candida albicans prosthetic valve endocarditis. Clin Infect Dis. 2004; 39:1253-4.
• [16]Dismukes WE, Karchmer AW, Buckley MJ, Austen WG, Swartz MN. Prosthetic Valve Endocarditis - Analysis of 38 Cases. Circulation. 1973; 48:365-377.
• [17]Garzoni C, Nobre VA, Garbino J. Candida parapsilosis endocarditis: a comparative review of the literature. Eur J Clin Microbiol Infect Dis. 2007; 26:915-26.
• [18]Ramani R, Gromadzki S, Pincus DH, Salkin IF, Chaturvedi V. Efficacy of API 20C and ID 32C systems for identification of common and rare clinical yeast isolates. J Clin Microbiol. 1998; 36:3396-8.
• [19]Fricker-Hidalgo H, Orenga S, Lebeau B, Pelloux H, Brenier-Pinchart MP, Ambroise-Thomas P, Grillot R. Evaluation of Candida ID, a new chromogenic medium for fungal isolation and preliminary identification of some yeast species. J Clin Microbiol. 2001; 39:1647-9.
• [20]Steinbach WJ, Perfect JR, Cabell CH, Fowler VG, Corey GR, Li JS, Zaas AK, Benjamin DK. A meta-analysis of medical versus surgical therapy for Candida endocarditis. J Infect. 2005; 51:230-47.
• [21]Sun XL, Zhang J, Wang GG, Zhuang XF, Yang YM, Zhu J, Tan HQ, Yu LT. Comparison of characteristics and short-term outcome from fungal infective endocarditis in prosthetic valve endocarditis versus native valve endocarditis. Am J Cardiol. 2013; 112:111-6.
• [22]Nguyen MH, Nguyen ML, Yu VL, McMahon D, Keys TF, Amidi M. Candida prosthetic valve endocarditis: prospective study of six cases and review of the literature. Clin Infect Dis. 1996; 22:262-7.
• [23]Melgar GR NR, Gordon SM, Lytle BW, Keys TF, Longworth DL. Fungal prosthetic valve endocarditis in 16 patients. An 11-year experience in a tertiary care hospital. Medicine. 1997; 76(2):94-103.
• [24]Samelson LE, Lerner SA, Resnekov L, Anagnostopoulos C. Relapse of Candida parapsilosis endocarditis after long-term suppression with flucytosin: retreatment with valve replacement and ketoconazole. Ann Intern Med. 1980; 93:838-9.